Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduction of Systemic Inflammation after Ischemic Stroke by Intravenous DNase (ReSCInD)
2024-516701-22-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of dornase alfa in ischemic stroke (2 arms), sponsored by LMU Klinikum. Primary endpoint: Primary endpoint: IL-1 β concentration in blood within 24±6 hours after symptom onset. Planned start Aug 2026; status: authorised.
02
Drugs
dornase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-516701-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516701-22-00.